{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:01:37Z","timestamp":1774944097192,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1007\/s11882-007-0013-3","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T10:37:22Z","timestamp":1180089442000},"page":"151-156","source":"Crossref","is-referenced-by-count":21,"title":["Tumor necrosis factor inhibitors for the treatment of asthma"],"prefix":"10.1007","volume":"7","author":[{"given":"Jiyoun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel G.","family":"Remick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,5,25]]},"reference":[{"issue":"1","key":"13_CR1","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1378\/chest.130.1_suppl.4S","volume":"130","author":"S.S. Braman","year":"2006","unstructured":"Braman SS: The global burden of asthma [review]. Chest 2006, 130(1 suppl):4S\u201312.","journal-title":"Chest"},{"key":"13_CR2","unstructured":"World Health Organization: Facts about asthma. In WHO Fact Sheet 2006. Available at: http:\/\/www.who.int\/mediacentre\/factsheets\/fs307\/en\/index.html . Accessed September 20, 2006."},{"key":"13_CR3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1398-9995.2004.00526.x","volume":"59","author":"M. Masoli","year":"2004","unstructured":"Masoli M, Fabian D, Holt S, et al.: The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004, 59:469\u2013478.","journal-title":"Allergy"},{"key":"13_CR4","doi-asserted-by":"crossref","first-page":"S482","DOI":"10.1067\/mai.2002.122716","volume":"109","author":"R. Beasley","year":"2002","unstructured":"Beasley R: The burden of asthma with specific reference to the United States. J Allergy Clin Immunol 2002, 109:S482\u2013S489.","journal-title":"J Allergy Clin Immunol"},{"key":"13_CR5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ccm.2005.10.001","volume":"27","author":"A.L. Wagelie-Steffen","year":"2006","unstructured":"Wagelie-Steffen AL, Kavanaugh AF, Wasserman SI: Biologic therapies for the treatment of asthma. Clin Chest Med 2006, 27:133\u2013147.","journal-title":"Clin Chest Med"},{"key":"13_CR6","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMe058266","volume":"354","author":"S.C. Erzurum","year":"2006","unstructured":"Erzurum SC: Inhibition of tumor necrosis factor alpha for refractory asthma. N Engl J Med 2006, 354:754\u2013758.","journal-title":"N Engl J Med"},{"key":"13_CR7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1042\/CS20050038","volume":"109","author":"C. Russo","year":"2005","unstructured":"Russo C, Polosa R: TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. Clin Sci (Lond) 2005, 109:135\u2013142.","journal-title":"Clin Sci (Lond)"},{"key":"13_CR8","first-page":"27","volume":"11","author":"R. Buhl","year":"2005","unstructured":"Buhl R: Anti-IgE antibodies for the treatment of asthma. Curr Opin Pulm Med 2005, 11:27\u201334.","journal-title":"Curr Opin Pulm Med"},{"key":"13_CR9","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.1016\/j.jaci.2004.12.1111","volume":"115","author":"J.A. Poole","year":"2005","unstructured":"Poole JA, Matangkasombut P, Rosenwasser LJ: Targeting the IgE molecule in allergic and asthmatic diseases: review of the IgE molecule and clinical efficacy. J Allergy Clin Immunol 2005, 115:S376\u2013S385.","journal-title":"J Allergy Clin Immunol"},{"key":"13_CR10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev.pharmtox.42.111901.111143","volume":"42","author":"P.J. Barnes","year":"2002","unstructured":"Barnes PJ: Cytokine modulators as novel therapies for asthma. Annu Rev Pharmacol Toxicol 2002, 42:81\u201398.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"13_CR11","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/thx.2005.045260","volume":"60","author":"P.H. Howarth","year":"2005","unstructured":"Howarth PH, Babu KS, Arshad HS, et al.: Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005, 60:1012\u20131018.","journal-title":"Thorax"},{"key":"13_CR12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1365-2222.2005.02407.x","volume":"36","author":"J. Kim","year":"2006","unstructured":"Kim J, McKinley L, Natarajan S, et al.: Anti-tumor necrosis factor-alpha antibody treatment reduces pulmonary inflammation and methacholine hyper-responsiveness in a murine asthma model induced by house dust. Clin Exp Allergy 2006, 36:122\u2013132.","journal-title":"Clin Exp Allergy"},{"key":"13_CR13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"S.B. Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, et al.: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323\u2013333.","journal-title":"Gastroenterology"},{"key":"13_CR14","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMct055183","volume":"355","author":"D.L. Scott","year":"2006","unstructured":"Scott DL, Kingsley GH: Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006, 355:704\u2013712.","journal-title":"N Engl J Med"},{"key":"13_CR15","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","volume":"72","author":"E.A. Carswell","year":"1975","unstructured":"Carswell EA, Old LJ, Kassel RL, et al.: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975, 72:3666\u20133670.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13_CR16","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1084\/jem.161.5.984","volume":"161","author":"B. Beutler","year":"1985","unstructured":"Beutler B, Mahoney J, Le Trang N, et al.: Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 1985, 161:984\u2013995.","journal-title":"J Exp Med"},{"key":"13_CR17","first-page":"1121","volume":"143","author":"G.K. Wollenberg","year":"1993","unstructured":"Wollenberg GK, DeForge LE, Bolgos G, et al.: Differential expression of tumor necrosis factor and interleukin-6 by peritoneal macrophages in vivo and in culture. Am J Pathol 1993, 143:1121\u20131130.","journal-title":"Am J Pathol"},{"key":"13_CR18","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/00024382-200115040-00005","volume":"15","author":"D.R. Call","year":"2001","unstructured":"Call DR, Nemzek JA, Ebong SJ, et al.: Differential local and systemic regulation of the murine chemokines KC and MIP2. Shock 2001, 15:278\u2013284.","journal-title":"Shock"},{"key":"13_CR19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/0006-291X(91)90478-P","volume":"174","author":"L.E. DeForge","year":"1991","unstructured":"DeForge LE, Remick DG: Kinetics of TNF, IL-6, and IL-8 gene expression in LPS-stimulated human whole blood. Biochem Biophys Res Commun 1991, 174:18\u201324.","journal-title":"Biochem Biophys Res Commun"},{"key":"13_CR20","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1073\/pnas.83.6.1670","volume":"83","author":"D. Caput","year":"1986","unstructured":"Caput D, Beutler B, Hartog K, et al.: Identification of a common nucleotide sequence in the 3\u2032-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci U S A 1986, 83:1670\u20131674.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13_CR21","first-page":"740","volume":"68","author":"E.D. Hsi","year":"1993","unstructured":"Hsi ED, Remick DG: Rapid determination of cell-associated tumor necrosis factor production by flow cytometry. Lab Invest 1993, 68:740\u2013745.","journal-title":"Lab Invest"},{"key":"13_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1357-2725(01)00097-8","volume":"34","author":"R.A. Black","year":"2002","unstructured":"Black RA: Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 2002, 34:1\u20135.","journal-title":"Int J Biochem Cell Biol"},{"key":"13_CR23","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.bbi.2003.12.009","volume":"18","author":"M. Haack","year":"2004","unstructured":"Haack M, Pollmacher T, Mullington JM: Diurnal and sleep-wake dependent variations of soluble TNF-and IL-2 receptors in healthy volunteers. Brain Behav Immun 2004, 18:361\u2013367.","journal-title":"Brain Behav Immun"},{"key":"13_CR24","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.4049\/jimmunol.152.10.5070","volume":"152","author":"J.F. Leeuwenberg","year":"1994","unstructured":"Leeuwenberg JF, Dentener MA, Buurman WA: Lipopolysaccharide LPS-mediated soluble TNF receptor release and TNF receptor expression by monocytes. Role of CD14, LPS binding protein, and bactericidal\/permeability-increasing protein. J Immunol 1994, 152:5070\u20135076.","journal-title":"J Immunol"},{"key":"13_CR25","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1128\/IAI.67.11.5579-5586.1999","volume":"67","author":"C. Truyens","year":"1999","unstructured":"Truyens C, Torrico F, Lucas R, et al.: The endogenous balance of soluble tumor necrosis factor receptors and tumor necrosis factor modulates cachexia and mortality in mice acutely infected with Trypanosoma cruzi. Infect Immun 1999, 67:5579\u20135586.","journal-title":"Infect Immun"},{"key":"13_CR26","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJM199606273342603","volume":"334","author":"C.J. Fisher Jr.","year":"1996","unstructured":"Fisher CJ, Jr., Agosti JM, Opal SM, et al.: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996, 334:1697\u20131702.","journal-title":"N Engl J Med"},{"key":"13_CR27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(87)91728-4","volume":"1","author":"A. Waage","year":"1987","unstructured":"Waage A, Halstensen A, Espevik T: Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987, 1:355\u2013357.","journal-title":"Lancet"},{"key":"13_CR28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jaci.2006.01.039","volume":"117","author":"S.T. Holgate","year":"2006","unstructured":"Holgate ST, Holloway J, Wilson S, et al.: Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. J Allergy Clin Immunol 2006, 117:496\u2013506; quiz 507.","journal-title":"J Allergy Clin Immunol"},{"key":"13_CR29","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1365-2222.1995.tb03249.x","volume":"25","author":"A. Shah","year":"1995","unstructured":"Shah A, Church MK, Holgate ST: Tumour necrosis factor alpha: a potential mediator of asthma. Clin Exp Allergy 1995, 25:1038\u20131044.","journal-title":"Clin Exp Allergy"},{"key":"13_CR30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1046\/j.1440-1711.2001.00980.x","volume":"79","author":"P.S. Thomas","year":"2001","unstructured":"Thomas PS: Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma. Immunol Cell Biol 2001, 79:132\u2013140.","journal-title":"Immunol Cell Biol"},{"key":"13_CR31","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.iac.2004.06.010","volume":"24","author":"K.S. Babu","year":"2004","unstructured":"Babu KS, Davies DE, Holgate ST: Role of tumor necrosis factor alpha in asthma. Immunol Allergy Clin North Am 2004, 24:583\u2013597.","journal-title":"Immunol Allergy Clin North Am"},{"key":"13_CR32","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.4049\/jimmunol.169.9.5287","volume":"169","author":"W.R. Coward","year":"2002","unstructured":"Coward WR, Okayama Y, Sagara H, et al.: NF-kappa B and TNF-alpha: a positive autocrine loop in human lung mast cells? J Immunol 2002, 169:5287\u20135293.","journal-title":"J Immunol"},{"key":"13_CR33","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa050580","volume":"354","author":"M.A. Berry","year":"2006","unstructured":"Berry MA, Hargadon B, Shelley M, et al.: Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006, 354:697\u2013708.","journal-title":"N Engl J Med"},{"key":"13_CR34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1084\/jem.174.1.103","volume":"174","author":"J.R. Gordon","year":"1991","unstructured":"Gordon JR, Galli SJ: Release of both preformed and newly synthesized tumor necrosis factor alpha (TNF-alpha)\/cachectin by mouse mast cells stimulated via the Fc epsilon RI. A mechanism for the sustained action of mast cell-derived TNF-alpha during IgE-dependent biological responses. J Exp Med 1991, 174:103\u2013107.","journal-title":"J Exp Med"},{"key":"13_CR35","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1164\/ajrccm.152.1.7599866","volume":"152","author":"P.S. Thomas","year":"1995","unstructured":"Thomas PS, Yates DH, Barnes PJ: Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med 1995, 152:76\u201380.","journal-title":"Am J Respir Crit Care Med"},{"key":"13_CR36","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.4049\/jimmunol.154.10.5411","volume":"154","author":"N.W. Lukacs","year":"1995","unstructured":"Lukacs NW, Strieter RM, Chensue SW, et al.: TNF-alpha mediates recruitment of neutrophils and eosinophils during airway inflammation. J Immunol 1995, 154:5411\u20135417.","journal-title":"J Immunol"},{"key":"13_CR37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1165\/ajrcmb.15.1.8679220","volume":"15","author":"T.B. Casale","year":"1996","unstructured":"Casale TB, Costa JJ, Galli SJ: TNF alpha is important in human lung allergic reactions. Am J Respir Cell Mol Biol 1996, 15:35\u201344.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"13_CR38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/rr12","volume":"1","author":"Y. Amrani","year":"2000","unstructured":"Amrani Y, Chen H, Panettieri RA Jr: Activation of tumor necrosis factor receptor 1 in airway smooth muscle: a potential pathway that modulates bronchial hyper-responsiveness in asthma? Respir Res 2000, 1:49\u201353.","journal-title":"Respir Res"},{"key":"13_CR39","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1165\/ajrcmb\/7.2.214","volume":"7","author":"M.F. Tosi","year":"1992","unstructured":"Tosi MF, Stark JM, Smith CW, et al.: Induction of ICAM-1 expression on human airway epithelial cells by inflammatory cytokines: effects on neutrophil-epithelial cell adhesion. Am J Respir Cell Mol Biol 1992, 7:214\u2013221.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"13_CR40","doi-asserted-by":"crossref","first-page":"592","DOI":"10.4049\/jimmunol.146.2.592","volume":"146","author":"M.H. Thornhill","year":"1991","unstructured":"Thornhill MH, Wellicome SM, Mahiouz DL, et al.: Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and-independent binding mechanisms. J Immunol 1991, 146:592\u2013598.","journal-title":"J Immunol"},{"key":"13_CR41","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jaci.2005.08.059","volume":"116","author":"P.J. Busse","year":"2005","unstructured":"Busse PJ, Zhang TF, Srivastava K, et al.: Chronic exposure to TNF-alpha increases airway mucus gene expression in vivo. J Allergy Clin Immunol 2005, 116:1256\u20131263.","journal-title":"J Allergy Clin Immunol"},{"key":"13_CR42","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1165\/ajrcmb.12.2.7865217","volume":"12","author":"S.J. Levine","year":"1995","unstructured":"Levine SJ, Larivee P, Logun C, et al.: Tumor necrosis factor-alpha induces mucin hypersecretion and MUC-2 gene expression by human airway epithelial cells. Am J Respir Cell Mol Biol 1995, 12:196\u2013204.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"13_CR43","doi-asserted-by":"crossref","first-page":"36510","DOI":"10.1074\/jbc.M507977200","volume":"280","author":"J.M. Lora","year":"2005","unstructured":"Lora JM, Zhang DM, Liao SM, et al.: Tumor necrosis factor-alpha triggers mucus production in airway epithelium through an IkappaB kinase beta-dependent mechanism. J Biol Chem 2005, 280:36510\u201336517.","journal-title":"J Biol Chem"},{"key":"13_CR44","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jaci.2005.05.034","volume":"116","author":"I.W. Choi","year":"2005","unstructured":"Choi IW, Sun K, Kim YS, et al.: TNF-alpha induces the late-phase airway hyperresponsiveness and airway inflammation through cytosolic phospholipase A(2) activation. J Allergy Clin Immunol 2005, 116:537\u2013543.","journal-title":"J Allergy Clin Immunol"},{"key":"13_CR45","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1164\/ajrccm\/145.2_Pt_1.332","volume":"145","author":"J.C. Kips","year":"1992","unstructured":"Kips JC, Tavernier J, Pauwels RA: Tumor necrosis factor causes bronchial hyperresponsiveness in rats. Am Rev Respir Dis 1992, 145:332\u2013336.","journal-title":"Am Rev Respir Dis"},{"key":"13_CR46","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cyto.2004.07.010","volume":"28","author":"S.T. Holgate","year":"2004","unstructured":"Holgate ST: Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease. Cytokine 2004, 28:152\u2013157.","journal-title":"Cytokine"},{"key":"13_CR47","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1517\/14656566.5.3.581","volume":"5","author":"E. Toussirot","year":"2004","unstructured":"Toussirot E, Wendling D: The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother 2004, 5:581\u2013594.","journal-title":"Expert Opin Pharmacother"},{"key":"13_CR48","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.taap.2004.10.005","volume":"205","author":"C. Bruce","year":"2005","unstructured":"Bruce C, Thomas PS: The effect of marimastat, a metalloprotease inhibitor, on allergen-induced asthmatic hyper-reactivity. Toxicol Appl Pharmacol 2005, 205:126\u2013132.","journal-title":"Toxicol Appl Pharmacol"},{"key":"13_CR49","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/gut.51.1.5","volume":"51","author":"S.J. Deventer van","year":"2002","unstructured":"van Deventer SJ: A place for TACE [comment]. Gut 2002, 51:5\u20136.","journal-title":"Gut"},{"key":"13_CR50","doi-asserted-by":"crossref","first-page":"L1047","DOI":"10.1152\/ajplung.2000.279.6.L1047","volume":"279","author":"D.G. Rudmann","year":"2000","unstructured":"Rudmann DG, Moore MW, Tepper JS, et al.: Modulation of allergic inflammation in mice deficient in TNF receptors. Am J Physiol Lung Cell Mol Physiol 2000, 279:L1047\u2013L1057.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"13_CR51","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000076441","volume":"133","author":"C. Zuany-Amorim","year":"2004","unstructured":"Zuany-Amorim C, Manlius C, Dalum I, et al.: Induction of TNF-alpha autoantibody production by AutoVac TNF106: a novel therapeutic approach for the treatment of allergic diseases. Int Arch Allergy Immunol 2004, 133:154\u2013163.","journal-title":"Int Arch Allergy Immunol"},{"key":"13_CR52","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1042\/CS20050289","volume":"110","author":"C.T. Bruce","year":"2006","unstructured":"Bruce CT, Thomas PS: TNF-alpha as a target for anti-asthma therapy [letter]. Clin Sci (Lond) 2006, 110:265.","journal-title":"Clin Sci (Lond)"},{"key":"13_CR53","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1046\/j.0818-9641.2003.01185.x","volume":"81","author":"I.K. Campbell","year":"2003","unstructured":"Campbell IK, Roberts LJ, Wicks IP: Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis. Immunol Cell Biol 2003, 81:354\u2013366.","journal-title":"Immunol Cell Biol"},{"key":"13_CR54","first-page":"640","volume":"61","author":"C. Oliveri","year":"2006","unstructured":"Oliveri C, Polosa R: Etanercept in chronic severe asthma [comment]. Thorax 2006, 61:640; author reply 640.","journal-title":"Thorax"},{"key":"13_CR55","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1517\/14740338.3.5.391","volume":"3","author":"R.M. Fleischmann","year":"2004","unstructured":"Fleischmann RM, Iqbal I, Stern RL: Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opin Drug Saf 2004, 3:391\u2013403.","journal-title":"Expert Opin Drug Saf"},{"key":"13_CR56","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00002018-200225030-00004","volume":"25","author":"R. Fleischmann","year":"2002","unstructured":"Fleischmann R, Iqbal I, Nandeshwar P, et al.: Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Saf 2002, 25:173\u2013197.","journal-title":"Drug Saf"},{"key":"13_CR57","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","volume":"48","author":"J.J. Gomez-Reino","year":"2003","unstructured":"Gomez-Reino JJ, Carmona L, Valverde VR, et al.: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003, 48:2122\u20132127.","journal-title":"Arthritis Rheum"},{"key":"13_CR58","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","volume":"38","author":"R.S. Wallis","year":"2004","unstructured":"Wallis RS, Broder MS, Wong JY, et al.: Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38:1261\u20131265.","journal-title":"Clin Infect Dis"},{"key":"13_CR59","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","volume":"44","author":"N. Mohan","year":"2001","unstructured":"Mohan N, Edwards ET, Cupps TR, et al.: Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001, 44:2862\u20132869.","journal-title":"Arthritis Rheum"},{"key":"13_CR60","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6","volume":"44","author":"W.H. Robinson","year":"2001","unstructured":"Robinson WH, Genovese MC, Moreland LW: Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001, 44:1977\u20131983.","journal-title":"Arthritis Rheum"},{"key":"13_CR61","first-page":"341","volume":"71","author":"L. Davydov","year":"2005","unstructured":"Davydov L: Omalizumab (Xolair) for treatment of asthma. Am Fam Physician 2005, 71:341\u2013342.","journal-title":"Am Fam Physician"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-007-0013-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11882-007-0013-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-007-0013-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:44:31Z","timestamp":1683852271000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11882-007-0013-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["13"],"URL":"https:\/\/doi.org\/10.1007\/s11882-007-0013-3","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}